Ticker

The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish. The heavy lifting is done.

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the cancer diagnostics company, has told shareholders it remains on track to deliver revenues of at least £2.1 million for 2026 as it searches for a new chief executive. The figure would represent a 50% increase on 2025.

Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset centred on cost reduction and a shift towards partner-led commercialisation of its Parsortix platform.

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4 million, underpinned by a commercial pipeline that has expanded 22% over the last quarter. The AIM-listed company has emerged from a year-long restructuring sharper and leaner, having cut its cost base substantially during…